Relapsed/Refractory Multiple Myeloma: Navigating Treatment Pathways

Please Log In or Register to continue.

Release Date: July 15, 2016
Expiration Date: July 15, 2017

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The management of multiple myeloma is rapidly changing due to the introduction of new therapies into the treatment landscape, including next-generation immunomodulatory agents and proteasome inhibitors, as well as immunotherapy and a histone deacetylase inhibitor. This activity will explain the various treatment pathways that exist for patients with relapsed or refractory multiple myeloma, of which clinical relapse can be defined as one or more of the following: development of new soft tissue plasmacytomas or bone lesions, definite increase in the size of existing plasmacytomas or bone lesions, hypercalcemia (>11.5 mg/dL), decrease in hemoglobin of >2 g/dL and/or a rise in serum creatinine by ≥2 mg/dL. In addition, the activity will discuss key takeaways from the pivotal clinical trials for these novel agents, providing clinicians with the data and rationales for selecting the most appropriate therapy for patients in the relapsed or refractory setting.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in relapsed/refractory multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the currently available treatment options for relapsed/refractory multiple myeloma and understand the rationale behind recommendations from clinical practice guidelines
  • Choose the best second-line treatment option for patients based on the current evidence, prior therapy, and patient characteristics such as age, comorbidity, and other risk factors

Agenda

Relapsed/Refractory Multiple Myeloma: Navigating Treatment Pathways – Jatin J. Shah, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 15, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Jatin J. Shah, MD
Associate Professor
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Jatin Shah received his medical degree from Ohio State University College of Medicine, Columbus, Ohio. He completed an internship and residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah is an associate professor and associate program director of the malignant hematology fellowship, as well as director of myeloma clinical and translational research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, Houston.

Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine. He is a member of the American Medical Association, American College of Physicians-American Society of Internal Medicine, American Society of Clinical Oncology, American Society of Hematology, American Association of Cancer Research, SWOG, and the International Myeloma Working Group. Dr. Shah is currently a reviewer for the British Journal of Hematology, Cancer, Leukemia, and The Oncologist. In addition, he is principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-096-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Jatin Shah has received grant support related to research activities from Array BioPharma, Celgene Corporation, Novartis AG, Onyx, Takeda Oncology, and Bristol-Myers Squibb Company.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Shah has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Shah has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.